Cancer Policy Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access May 23, 2025Vol.51 No.20By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer May 23, 2025Vol.51 No.20
Drugs & Targets FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression May 16, 2025Vol.51 No.19
Drugs & Targets FDA approves Zynyz as first-line treatment for advanced anal cancer May 16, 2025Vol.51 No.19
Regulatory News Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies May 09, 2025Vol.51 No.18By Claire Marie Porter
Cancer Policy Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Cancer Policy First ODAC meeting since Trump’s inauguration scheduled for May 20-21 May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC May 09, 2025Vol.51 No.18
Clinical Roundup Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment May 02, 2025Vol.51 No.17
